Vor Biopharma (NASDAQ:VOR) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Vor Biopharma (NASDAQ:VOR) from a hold rating to a sell rating in a research note released on Saturday.

VOR has been the topic of several other reports. Jefferies Financial Group upgraded shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. HC Wainwright cut their target price on shares of Vor Biopharma from $32.00 to $31.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Finally, Wedbush increased their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Vor Biopharma currently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Price Performance

VOR opened at $14.63 on Friday. Vor Biopharma has a one year low of $3.20 and a one year high of $65.80. The company’s 50 day simple moving average is $15.11 and its 200-day simple moving average is $14.23. The stock has a market capitalization of $792.80 million, a P/E ratio of -0.04 and a beta of 1.75.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, analysts anticipate that Vor Biopharma will post -3.56 EPS for the current year.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of Vor Biopharma stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total value of $2,604,415.50. Following the sale, the director directly owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 3,002,903 shares of company stock valued at $49,412,176. 0.45% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. Goldman Sachs Group Inc. increased its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Vor Biopharma in the 1st quarter valued at about $140,000. XTX Topco Ltd bought a new position in shares of Vor Biopharma in the 2nd quarter valued at about $66,000. BNP Paribas Financial Markets grew its position in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after acquiring an additional 5,058 shares during the period. Finally, Squarepoint Ops LLC bought a new position in shares of Vor Biopharma in the 3rd quarter valued at about $230,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).